|
1
|
Mugnaini EN and Ghosh N: Lymphoma. Prim
Care. 43:661–675. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Monfardini S, Zagonel V and Noordijk EM:
Lymphomas. Crit Rev Oncol Hematol. 27:157–160. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu-Monette ZY, Wu L, Visco C, Tai YC,
Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et
al: Mutational profile and prognostic significance of TP53 in
diffuse large B-cell lymphoma patients treated with R-CHOP: Report
from an international DLBCL rituximab-CHOP consortium program
study. Blood. 120:3986–3996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martelli M, Ferreri AJ, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang W and Huang H: The evolution and
curative effect of diffuse large B cell lymphoma treatment in
China. Zhonghua Xue Ye Xue Za Zhi. 35:357–360. 2014.(In Chinese).
PubMed/NCBI
|
|
6
|
Schürch CM, Federmann B,
Quintanilla-Martinez L and Fend F: Tumor heterogeneity in
lymphomas: A different breed. Pathobiology. 85:130–145. 2018.
View Article : Google Scholar
|
|
7
|
Matasar MJ and Zelenetz AD: Overview of
lymphoma diagnosis and management. Radiol Clin North Am. 46175–198.
(vii)2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Larrabeiti-Etxebarria A, Lopez-Santillan
M, Santos-Zorrozua B, Lopez-Lopez E and Garcia-Orad A: Systematic
review of the potential of MicroRNAs in diffuse large B cell
lymphoma. Cancers (Basel). 11:1442019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu M, Wang G, Tian W, Deng Y and Xu Y:
MiRNA-based therapeutics for lung cancer. Curr Pharm Des.
23:5989–5996. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du X, Zhang J, Wang J, Lin X and Ding F:
Role of miRNA in lung cancer-potential biomarkers and therapies.
Curr Pharm Des. 23:5997–6010. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kabekkodu SP, Shukla V, Varghese VK,
D'Souza J, Chakrabarty S and Satyamoorthy K: Clustered miRNAs and
their role in biological functions and diseases. Biol Rev Camb
Philos Soc. 93:1955–1986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vishnoi A and Rani S: MiRNA biogenesis and
regulation of diseases: An overview. Methods Mol Biol. 1509:1–10.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Kong X, Shi Q and Zhao B:
MicroRNA-383-5p acts as a potential prognostic biomarker and an
inhibitor of tumor cell proliferation, migration, and invasion in
breast cancer. Cancer Biomark. 27:423–432. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei C and Gao JJ: Downregulated miR-383-5p
contributes to the proliferation and migration of gastric cancer
cells and is associated with poor prognosis. PeerJ. 7:e78822019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu G, Li N, Zhang Y, Zhang J, Xu R and Wu
Y: MicroRNA-383-5p inhibits the progression of gastric carcinoma
via targeting HDAC9 expression. Braz J Med Biol Res. 52:e83412019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang J, Xie C, Liu Y, Shi Q and Chen Y:
Up-regulation of miR-383-5p suppresses proliferation and enhances
chemosensitivity in ovarian cancer cells by targeting TRIM27.
Biomed Pharmacother. 109:595–601. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao S, Gao X, Zang S, Li Y, Feng X and
Yuan X: MicroRNA-383-5p acts as a prognostic marker and inhibitor
of cell proliferation in lung adenocarcinoma by cancerous inhibitor
of protein phosphatase 2A. Oncol Lett. 14:3573–3579. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao B, Fu X, Li X, Li Y and Gan N:
RP11-284F21.9 promotes oral squamous cell carcinoma development via
the miR-383-5p/MAL2 axis. J Oral Pathol Med. 49:21–29. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng B, Xi Z, Liu R, Yin W, Sui Z, Ren B,
Miller H, Gong Q and Liu C: The function of MicroRNAs in B-cell
development, lymphoma, and their potential in clinical practice.
Front Immunol. 9:9362018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fernando TR, Rodriguez-Malave NI and Rao
DS: MicroRNAs in B cell development and malignancy. J Hematol
Oncol. 5:72012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Yébenes VG, Bartolomé-Izquierdo N and
Ramiro AR: Regulation of B-cell development and function by
microRNAs. Immunol Rev. 253:25–39. 2013. View Article : Google Scholar
|
|
24
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia; Lymphoma Group and Eastern Cooperative Oncology Group, ;
et al: Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano
classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Wang L, Ma Y, Han T and Huang M:
The enhanced international prognostic index for diffuse large
B-cell lymphoma. Am J Med Sci. 353:459–465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li XD, Li XM, Gu JW and Sun XC: MiR-155
regulates lymphoma cell proliferation and apoptosis through
targeting SOCS3/JAK-STAT3 signaling pathway. Eur Rev Med Pharmacol
Sci. 21:5153–5159. 2017.PubMed/NCBI
|
|
28
|
Jia YJ, Liu ZB, Wang WG, Sun CB, Wei P,
Yang YL, You MJ, Yu BH, Li XQ and Zhou XY: HDAC6 regulates
microRNA-27b that suppresses proliferation, promotes apoptosis and
target MET in diffuse large B-cell lymphoma. Leukemia. 32:703–711.
2018. View Article : Google Scholar : PubMed/NCBI
|
